{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:09:09Z","timestamp":1791544149208,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":2444,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1111\/jth.13237","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T02:36:41Z","timestamp":1451356601000},"page":"421-426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Biosimilars of low\u2010molecular\u2010weight heparin products: fostering competition or reducing \u2018biodiversity\u2019?"],"prefix":"10.1016","volume":"14","author":[{"given":"J.","family":"Harenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cimminiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Agnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Di Minno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Polo Friz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Prandoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Scaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.13237_bb0010","unstructured":"Drug Price Competition and Patent Term Restoration Act. [Public Law 98\u2013417], 1984."},{"issue":"14 Suppl 6","key":"10.1111\/jth.13237_bb0015","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.2146\/ajhp080210","article-title":"Biosimilars: policy, clinical, and regulatory considerations","volume":"65","author":"Gottlieb","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"10.1111\/jth.13237_bb0020","series-title":"Biological Approvals by Year. Vaccines, Blood & Biologics","year":"2014"},{"key":"10.1111\/jth.13237_bb0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/CEOR.S12494","article-title":"Biosimilar medicines and cost\u2010effectiveness","volume":"3","author":"Simoens","year":"2011","journal-title":"Clinicoecon Outcomes Res"},{"issue":"2 Suppl","key":"10.1111\/jth.13237_bb0030","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1378\/chest.1412S3","article-title":"Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines","volume":"141","author":"Guyatt","year":"2012","journal-title":"Chest"},{"key":"10.1111\/jth.13237_bb0035","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1160\/TH09-02-0081","article-title":"Structural features of low\u2010molecular\u2010weight heparins affecting their affinity to antithrombin","volume":"102","author":"Bisio","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13237_bb0040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1055\/s-0035-1544228","article-title":"Thromboprophylaxis with low\u2010molecular\u2010weight heparins: an assessment of the methodological quality of studies","volume":"41","author":"Agnelli","year":"2015","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 3","key":"10.1111\/jth.13237_bb0045","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1016\/S0049-3848(11)70027-5","article-title":"Overview on guidelines and recommendations for generic low\u2010molecular\u2010weight heparins","volume":"127","author":"Harenberg","year":"2011","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13237_bb0050","series-title":"Guidelines on Clinical and Non\u2010Clinical Development of Medicinal Products Containing Low\u2010Molecular\u2010Weight Heparins","year":"2009"},{"key":"10.1111\/jth.13237_bb0055","unstructured":"FDA News Release, July 23, 2010. www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm220092.htm. Accessed 5 May 2013."},{"key":"10.1111\/jth.13237_bb0060","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/jth.12269","article-title":"Update of the recommendations on biosimilar low\u2010molecular\u2010weight heparins from the Scientific Subcommittee on Control of Anticoagulation of the International Society on Thrombosis and Haemostasis","volume":"11","author":"Harenberg","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13237_bb0065","unstructured":"U.S. Department of Health and Human Services. Food and Drug Administration. Docket No. FDA\u20102010\u2010N\u20100477. Approval pathway for biosimilar and interchangeable biological products. Public Hearing November 2010."},{"key":"10.1111\/jth.13237_bb0070","unstructured":"www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm220037.htm. 2010. Accessed November 2014."},{"key":"10.1111\/jth.13237_bb0075","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use. Guidelines on non clinical and clinical development of similar biological medicinal products containing low molecular weight heparin. www.emea.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003927.pdf. 2009. Accessed November 2014."},{"key":"10.1111\/jth.13237_bb0080","unstructured":"The World Health Organization Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs). www.who.int\/entity\/bio\u00aclogicals\/areas\/biological_therapeutics\/BIOTHERAPEUTICS_FOR_WEBj2 Accessed 20 April 2009."},{"key":"10.1111\/jth.13237_bb0085","unstructured":"www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/10\/WC500176768.pdf. Accessed April 2015."},{"key":"10.1111\/jth.13237_bb0090","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.drudis.2012.11.002","article-title":"Low molecular weight heparins copies: are they considered to be generics or biosimilars?","volume":"18","author":"Minghetti","year":"2013","journal-title":"Drug Discov Today"},{"key":"10.1111\/jth.13237_bb0095","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A comparison of low\u2010molecular\u2010weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in Non\u2010Q\u2010Wave coronary events study group","volume":"337","author":"Cohen","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13237_bb0100","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","article-title":"Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non\u2010Q\u2010wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1111\/jth.13237_bb0105","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa060898","article-title":"Enoxaparin versus unfractionated heparin with fibrinolysis for ST\u2010elevation myocardial infarction","volume":"354","author":"Antman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13237_bb0110","first-page":"45","article-title":"Enoxaparin vs unfractionated heparin in high\u2010risk patients with non\u2010ST\u2010segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial","volume":"292","author":"Ferguson","year":"2004","journal-title":"JAMA"},{"key":"10.1111\/jth.13237_bb0115","first-page":"319","article-title":"Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial","volume":"73","author":"Gallo","year":"2009","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1111\/jth.13237_bb0120","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0735-1097(00)00889-5","volume":"36","author":"Braunwald","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.13237_bb0125","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0002-9149(03)00105-X","article-title":"Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non\u2010ST\u2010segment elevation acute myocardial infarction (the ARMADA study)","volume":"91","author":"Montalescot","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1111\/jth.13237_bb0130","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0735-1097(00)00695-1","article-title":"Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina","volume":"36","author":"Montalescot","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.13237_bb0135","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1161\/01.CIR.98.4.294","article-title":"Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. Investigators of the ESSENCE Trial","volume":"98","author":"Montalescot","year":"1998","journal-title":"Circulation"},{"key":"10.1111\/jth.13237_bb0140","doi-asserted-by":"crossref","first-page":"E158","DOI":"10.1177\/1076029610392216","article-title":"Differences of present recommendations and guidelines for generic low\u2010molecular\u2010weight heparins: is there room for harmonization","volume":"17","author":"Harenberg","year":"2011","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1111\/jth.13237_bb0145","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1046\/j.1365-2141.2003.04334.x","article-title":"Heparin\u2010induced thrombocytopenia: pathogenesis and management","volume":"121","author":"Warkentin","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.13237_bb0150","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/1076029610393332","article-title":"An open label, non\u2010randomized, prospective clinical trial evaluating the immunogenicity of branded enoxaparin versus generics in healthy volunteers","volume":"17","author":"Gomes","year":"2011","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1111\/jth.13237_bb0155","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1586\/17474086.1.1.75","article-title":"Risk of heparin\u2010induced thrombocytopenia in patients receiving thromboprophylaxis","volume":"1","author":"Greinacher","year":"2008","journal-title":"Expert Rev Hematol"},{"issue":"Suppl 1","key":"10.1111\/jth.13237_bb0160","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.thromres.2008.08.005","article-title":"Low\u2010molecular\u2010weight heparin use in the obese, elderly, and in renal insufficiency","volume":"123","author":"Clark","year":"2008","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13237_bb0165","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1056\/NEJMe0803599","article-title":"Heparin comes clean","volume":"358","author":"Schwartz","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13237_bb0170","unstructured":"Woodcock J. (MD Director, CDER). Proposal for Reintroduction of Bovine Heparin to the US Market. FDA Science Board Meeting \u2013 June 4, 2014. www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/ScienceBoardtotheFoodandDrugAdministration\/ucm399395.htm Accessed 24 November 2015 www.fda.gov\/downloads\/UCM399418.pdf Accessed 24 November 2015."},{"key":"10.1111\/jth.13237_bb0175","unstructured":"World Federation of Hemophilia (WFH). 2012. Registry of Clotting Factor Concentrates (9th Edition). Available from: www1.wfh.org\/publications\/files\/pdf-1472.pdf. Accessed December 2014."},{"key":"10.1111\/jth.13237_bb0180","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10198-013-0538-4","article-title":"Are biosimilars the next tool to guarantee cost\u2010containment for pharmaceutical expenditures?","volume":"15","author":"Farfan\u2010Portet","year":"2014","journal-title":"Eur J Health Econ"},{"key":"10.1111\/jth.13237_bb0185","doi-asserted-by":"crossref","first-page":"c1","DOI":"10.1159\/000319640","article-title":"Biosimilars and regulatory authorities","volume":"117","author":"Minghetti","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"10.1111\/jth.13237_bb0190","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1160\/TH06-09-0513","article-title":"Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study","volume":"97","author":"Mah\u00e9","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13237_bb0195","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low\u2010molecular\u2010weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13237_bb0200","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/1471-2407-13-284","article-title":"CATCH: a randomised clinical trial comparing long\u2010term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients","volume":"13","author":"Lee","year":"2013","journal-title":"BMC Cancer"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13237","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13237","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622045792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622045792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.13237\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:16:12Z","timestamp":1761534972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622045792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S1538783622045792"],"URL":"https:\/\/doi.org\/10.1111\/jth.13237","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biosimilars of low\u2010molecular\u2010weight heparin products: fostering competition or reducing \u2018biodiversity\u2019?","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.13237","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}